INBX · Inhibrx Biosciences, Inc.

$123.41 -0.52 (-0.42%) At close · Aug 28

Russell 2000 member Rebalance outlook locked

Market Cap

$1.82B

14.72M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-05-30	2026 American Society of Clinical Oncology (ASCO) Annual Meeting	Shareholder meeting
2026-05-11	Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC	Earnings call
2026-04-21	Inhibrx Biosciences Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer	Webcast
2026-03-12	ESMO Sarcoma and Rare Cancers Congress 2026	Event
2026-02-25	British Sarcoma Group Annual Conference 2026	Conference
2025-11-22	2025 Society for NeuroOncology Annual Meeting	Shareholder meeting
2025-11-14	The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study	Event
2025-11-05	21st Annual Industry/Academia Precision Oncology & Radmed Symposium	Event
2025-10-23	Inhibrx Announces ozekibart (INBRX-109) Phase 2 results in Chondrosarcoma and Provides Update on CRC and Ewing Cohorts	Earnings call
2025-06-02	2025 American Society of Clinical Oncology (ASCO) Annual Meeting	Shareholder meeting

Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 147 filings 143 filers Visit website